Vimarsana
Biggest News Aggregation in the World

Allogeneic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Allogeneic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Allogeneic Today - Breaking & Trending Today

Monthly information on share capital and company voting - Vimarsana News

Monthly information on share capital and company voting

(Article 223-16 of General Regulation of the French financial markets authority)...

Neupogen Biosimilar Nivestym Matches Efficacy for Allogeneic HSCT Donor Mobilization - Vimarsana News

Neupogen Biosimilar Nivestym Matches Efficacy for Allogeneic HSCT Donor Mobilization

A single-center cohort analysis showed the biosimilar provided similar PBSC mobilization to originator filgrastim.

Bone Marrow Transplant: Adult Allogeneic Bone Marrow Transplant | Zulekha Yenepoya Institute of Oncology | Mangaluru News - Vimarsana News

Bone Marrow Transplant: Adult Allogeneic Bone Marrow Transplant | Zulekha Yenepoya Institute of Oncology | Mangaluru News

Learn about the successful adult allogeneic bone marrow transplant performed at Zulekha Yenepoya Institute of Oncology. Find out how a 40-year-old man with relapsed acute myeloid leukaemia underwent a haploidentical transplant and recovered with minimal complications.

Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy - Vimarsana News

Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy

Poseida is a clinical-stage biotechnology company dedicated to advancing a new class of cancer cell therapy and gene therapy products using genetic engineering technologies Astellas to invest a total of $50 million to acquire approximately 8.8% of Poseida and to receive a right of exclusive negotiation and first refusal for any potential partnering of P-MUC1C-ALLO1, an allogeneic CAR-T cell therapy product candidate for solid tumors Astellas will have the right to designate an obser...

Tessa Therapeutics' 'Off-the-Shelf' CAR-T Therapy Shows - Vimarsana News

Tessa Therapeutics' 'Off-the-Shelf' CAR-T Therapy Shows

78% Overall Response Rate (14/18 patients), including seven patients exhibiting a complete response to TT11X allogeneic CAR-T therapySafety data...